GLP-3 | Retatrutide

€100.00

Technical Specifications

Specification	Detail
Product Name	Retatrutide (LY3437943) – R&D Only
Common Name	GLP-3 / Triple-G
CAS Number	2381089-83-2
Molecular Formula	C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight	4731.33 Da
Purity	≥99% (HPLC verified)
Appearance	White to off-white lyophilized powder
Solubility	Soluble in water, PBS, and appropriate buffers
Target Receptors	GLP-1R, GIPR, GCGR
Mechanism	Triple hormone receptor agonist
Half-Life	Approximately 6 days
Key Research Applications	Obesity, T2DM, osteoarthritis, OSA, MASLD, cardiovascular research
Storage (Powder)	-20°C; protect from light and moisture
Storage (Reconstituted)	2-8°C (short-term); -20°C (long-term, aliquot)
Shipping	Ambient temperature with protective packaging
Intended Use	Research and laboratory use only
Documentation	Certificate of Analysis provided with each batch

Category: Buy Peptide Online EU Tags: -20°C storage, 150 minutes, 2-AG, 2-NBDG, 3Rs principle, abdominal pain, ABSL, academic collaboration, academic discount peptide, ACC, accelerate discovery, accelerated approval, access to care, accumulation, acetylation, acetylcholine, ACOX, act now, active aging, activity monitoring, acute kidney injury, ADA, adaptive pathway, Adaptive thermogenesis, adherence, adiponectin, Adipose tissue, adipose tissue macrophage, adjustable gastric band, ADME research, adoption, advanced research, adventitious agent, adverse event, adverse event reporting, advisory board, advocacy, aerobic exercise, affordable research peptides, age-friendly, aging biology, aging clock, aging population, aging research, AgRP, AI, Aib peptide, AKI, Akt, albumin binding peptide, albuminuria, algorithm-driven, allergy, allometric scaling, alloxan, ALS, ALT, altered intercellular communication, Alzheimer's disease, amber vial, Ames test, amidation, amino acid metabolism, amino acid sequence, AMPK, amylin, anakinra, analgesia, analog synthesis, analytical standard, anandamide, anaphylaxis, anchorage-independent growth, anesthesia, Angiogenesis, animal biosafety level, animal care committee, animal model, animal rule, animal study peptides, animal welfare, animal welfare research, anti drug antibody, anti-obesity peptide, antioxidant, aortic ring, aortic ring assay, apoptosis, appetite loss, appetite suppression research, applied research, artificial intelligence, Artificial pancreas, AS160, Aseptic technique, AST, atherosclerosis, ATM, ATP production, attention, audit, autoclave, autoinjector, automated insulin delivery, autonomic neuropathy, autophagy, AVMA guidelines, avoid freeze-thaw, awareness campaign, B cell, B12, back in stock alert, backorder peptide, bacteriostatic water, balance, balance test, bank transfer peptide, bariatric surgery, basal metabolic rate, BAT, batch release, BDNF, BE study, behavioral testing, behavioral therapy, beige adipose tissue, bench to bedside, best price guarantee, best-in-class potential, Beta arrestin, beta-galactosidase, bile acid synthesis, bile acids, biliary tract disease, bilirubin, bilirubin elevation, binding affinity, Bioactive peptide, bioanalytical chemistry, bioavailability, bioburden, biochemicals for research, biocompatibility, bioequivalence, bioinformatics, biomarker detection, Biomarker driven, biomarker research, Biosafety cabinet, biosimilar, biostatistics, Biotech startup, biotin label, BLA, bleeding time, blinding, blister pack, bloating, BMR, body composition, bombesin, bone mineral density, Boyden chamber, BPC-157 Europe, brain reserve, brain tissue, BrdU, break new ground, breakthrough therapy, brown adipose tissue, browning, bruising, BSc, bulk Retatrutide, BUN, bundle deal, burden of disease, business continuity, buy 2 get 1 free, buy GLP-3, buy peptides EU, buy peptides France legally, buy peptides Germany safely, Buy peptides online, buy research peptides, buy retatrutide, buy Retatrutide Germany, C-peptide, C20 diacid, calcium, Caloric restriction, calorie restriction mimetic, CAM assay, cAMP assay, canakinumab, Cancer cachexia, CAPA, Carcinogenicity, Cardiac hypertrophy, cardiology, cardiovascular research peptides, cardiovascular risk reduction, CART, cartridge, catalase, CB1 receptor, CCK, CCK-8, CD31 staining, cell culture peptides, cell cycle analysis, cell death, cell sorting, cell transformation, cell-based assay, Cellular Senescence, Certificate of Analysis, CFS, CGA, CGM, CGRP, chair stand, change control, chemical fume hood, chemical hygiene, chemical hygiene plan, chemical resistant glove, chemotaxis, child-resistant, cholecystitis, cholelithiasis, cholesterol, cholesterol synthesis, choline-deficient diet, Chromatin remodeling, chromosome aberration, chronic disease management, chronic disease research, chronic inflammation, chronic kidney disease, citizen science, CKD, clean eating, cleaning validation, cleanroom, clearance, clinical candidate, clinical frailty scale, clinical guideline, clinical holds, clinical proof of concept, clinical study report, clinical study support, clock drawing, Closed loop system, CME, CoA, coagulation assay, coating, Cognitive function, cognitive reserve, cold chain management, cold exposure, cold-induced thermogenesis, collaborative research, combination therapy, Comet assay, commercial research, commercialization, community-driven, comparative medicine, compatibility, competent authority, competitive landscape, complete your research panel, compliance, comprar retatrutide España, comprehensive geriatric assessment, conditional approval, confidence in data, confirmatory trial, connected device, consensus statement, constipation, container closure, container closure integrity, containment, continuous glucose monitor, continuous monitoring, convenience, coolant pack shipping, corrective action, cost utility, cost-effectiveness, CPT1, CR mimetic, creatinine, credit card peptide, CRO services, cryptocurrency peptide, CSR, Custom order, custom peptide synthesis, customer service peptide, customer testimonials, customs-friendly peptides, cutting-edge peptide, CYP7A1, cytokine analysis, cytokine storm, DALY, DASH diet, data science, Data sharing, db/db mouse, delayed gastric emptying, delivery accuracy, dementia-friendly, dendritic cell, deviation report, DEXA scan, diabetes epidemic, diabetes research peptides, diabetic nephropathy, Diabetic Retinopathy, diabetology, diarrhea, diet, Diet induced obesity, diet-induced thermogenesis, dietary intervention, dietetics, digital health, digital pill, DILI, DIO mouse, disability-adjusted life year, discontinuation, discovery research, discreet shipping peptides, disease awareness, disinfection, disposal consideration, DIY looping, DMSO for peptides, DNA damage, DNA methylation, docking study, dopamine, dose ranging study, double gloving, DPP-4 inhibitor, drug approval process, drug development peptide, drug development service, drug discovery peptide, drug interaction study, drug target validation, drug-drug interaction, dual agonist, duodenal switch, DXA, dyspepsia, ease of use, EC50 Retatrutide, ECAR, Ectopic fat, EdU, efficacy study, eGFR, elastomer, elevate your research, elevated plus maze, Eli Lilly Retatrutide, ELISA kit, EMA, EMA guidelines, email support peptide, encrypted payment, Endocannabinoid, endocrinology, endothelial function, endotoxemia, Endotoxin testing, endurance training, energy center, energy expenditure research, Energy homeostasis, enforcement action, Enterohepatic circulation, enzyme complementation, eosinophil, epicardial fat, epidemiology, epigenetic age, epigenetic alteration, episodic memory, ePRO, EQ-5D, equipment qualification, ER stress, erythema, essential research tool, ethical approval, Ethical research, EU based supplier, EU peptide shop, eupeptideshop.org, European laboratory supply, European peptide supplier, European Research Council, euthanasia, exceptional circumstances, exclusivity, executive function, exercise, Exercise mimetic, Exercise physiology, exercise prescription, Expert opinion, expiry dating, exploratory research, explore the science, exposure-response, express shipping peptide, extractable leachable, extractable volume, FAAH, face shield, facility qualification, FACS, fall prevention, falls clinic, family practice, FAQ peptide, FAS, fast delivery peptide, Fast Shipping Peptides EU, fast track, Fasting glucose, Fasting mimicking diet, fat mass, fatty acid amide, fatty acid conjugated peptide, Fatty acid oxidation, fatty liver disease research, FDA, FDA guidelines, fed glucose, Ferroptosis, FGF21, FGM, FIH, finished product, first aid measure, first-in-class molecule, first-in-human, fitness tracker, flash glucose monitor, flatulence, flexibility, flexitarian diet, flow cytometry, Fluorescence polarization, fluorescence tag, folate, follow-up, food effect, food intake study, FOR RESEARCH USE ONLY, forced degradation, formulary access, FoxO, FP, fracture liaison service, fracture risk, frailty, frailty index, frailty syndrome, freezer storage, FRET assay, fried frailty phenotype, fullness, functional assay peptide, functional medicine, functional testing, fundamental science, future of medicine, G6Pase, GABA, gait speed, gallbladder disease, gastric bypass, gastrin, gastroenterology, gastroesophageal reflux, gastroparesis, GCGR EC50, GCP guideline, GDF15, GDP guideline, gene expression analysis, gene regulation, generic drug, genomic instability, Genotoxicity, GERD, geriatric assessment, geriatric study, geroprotector, geroscience, GGT, Ghrelin, GHS labeling, GI tract, GIP research, GIPR EC50, glass vial, glide force, Global health, global health research, glove box, GLP guideline, GLP-1 GIP Glucagon agonist, GLP-1 research, GLP-1R EC50, GLP-3 for sale, GLP-3 peptide, GLP-3 research, GLP-3 vs Retatrutide, glucagon level, glucagon research, Gluconeogenesis, glucose control research, glucose metabolism, glucose tolerance test, glucose uptake, GLUT4 translocation, glutamate, glycogen content, Glycogen synthesis, glycolysis, GMP grade peptide, GMP guideline, goggles, gold standard peptide, GPX, grip strength, GRP, GSH, GSK3beta, GTT, Gut hormone, Gut microbiome, hair net, HALE, half-life change, hallmarks of aging, handling instruction, handling video, hard-to-find peptide, hazard identification, HbA1c measurement, HDL, health authority, Health Canada, Health disparity, health economics, health equity, Health literacy, health technology assessment, healthspan, healthspan extension, Healthy aging, healthy life expectancy, healthy obese, Heart failure, heat shock response, hemostasis, hepatic impairment, hepatology, hepatology research, HIF-1alpha, High income country, high purity peptides Germany, high-end research chemical, high-fat diet, high-throughput screening, highly sought-after peptide, HIIT, Histamine, histology, Histone modification, hit-to-lead, HMGCR, HMGCS2, holistic health, Horizon Europe funding, hormesis, hospital research, HPLC analysis, HTA, human factors, human trial preparation, humane endpoint, Humanized mouse, humidity study, Huntington's disease, Hy's law, hypersensitivity, hypertension, Hypothalamus, hypothesis-driven, Hypoxia, IACUC, IB, IBC, ICER, ICH guideline, IGF-1, IHC, IL-1 receptor antagonist, IL-1beta, IL-6, immunogenicity, immunohistochemistry, immunometabolism, immunosenescence, impact of weight on quality of life, impact on efficacy, impact on safety, impurity synthesis, in high demand, In stock peptide, in vitro research, in vivo research, in-process control, incoming inspection, incretin research, IND application, IND enabling studies, indirect calorimetry, industry partnership, inflammaging, inflammation resolution, Inflammatory markers, injection force, injection site necrosis, injection site reaction, injection technique, innovative research, innovative research tool, innovator drug, inspection, institutional billing peptide, institutional biosafety committee, Insulin pump, insulin sensitivity research, Insulin signaling, insulin therapy, insulin tolerance test, integrative medicine, interchangeable, Intermittent fasting, internal medicine, interval training, introductory price, invasion assay, investigator brochure, invoice payment peptide, IP, iron, IRS-1, Ischemia reperfusion, ISO certified lab, ITC, ITT, IWQOL, JAK inhibitor, join the forefront, ketogenesis, Ketogenic diet, ketone bodies, key opinion leader, Ki67, kidney function, kinetic assay, Knockout mouse, KOL, Lab coat, lab safety, lab safety training, lab shoe, Lab Tested Peptides, label, labeling verification, laboratory peptides Netherlands, laboratory reagents, laboratory use only, LAL test, laminar flow hood, launch, LDH release, LDL, LDL receptor, lead optimization, Lean mass, learning, leptin, leukotriene, lifespan, lifespan extension, lifestyle medicine, lifestyle modification, light activity, light-dark box, limited stock, line extension, lipid mediator, Lipid metabolism, lipid panel, Lipid Peroxidation, Lipidomics, lipogenesis, lipohypertrophy, live chat support, live/dead staining, liver biopsy, Liver Disease Research, liver enzymes, Liver fat, liver fat quantification, liver injury, liver steatosis research, long term extension, long-acting peptide, long-term care, longevity economy, longevity study, loss of proteostasis, lot release, low grade inflammation, Low income country, low-carb diet, Loyalty discount, LPS, LTE, lupus-like syndrome, LY3437943, lyophilization service, lyophilized peptides, lysosome, M1 macrophage, M2 macrophage, MAA, machine learning, macular edema, MAGL, maintenance, make an informed decision, malabsorption, maresin, margin of safety, market access, market analysis peptide, market share, market withdrawal, marketing authorization, MASLD research, mass spec peptide, mast cell, material safety data sheet, Matrigel plug, maximum dose, Maximum tolerated dose, MCD diet, MCH, MDA, mechanism study, medical center, medical education, medication guide, medicinal chemistry, Mediterranean diet, memory, Metabolic chamber, metabolic disease research, Metabolic health, Metabolic research peptide, metabolic surgery, Metabolic syndrome research, Metabolically healthy obese, metabolite profiling, metabolite synthesis, Metabolomics, metaflammation, metagenomics, metformin, method development, method validation, mHealth, MHO, microbial limit, micronucleus test, Middle income country, migration assay, mineral deficiency, mitochondrial dysfunction, Mitochondrial Membrane Potential, mitochondrial respiration, Mitophagy, mixing, MMSE, mobile health, MoCA, moderate activity, modify peptide, molarity calculator peptide, molecular modeling, monitoring, morbidity, motilin, mouse model, MRI imaging, MSDS, mTOR, mTOR signaling, MTS, MTT, multiple sclerosis, multivitamin, Muscle fat, muscle mass, muscle tissue, Muscle wasting, Must have peptide, Mutagenicity, mycoplasma testing, Myocardial infarction, myograph, N95 mask, nAb, NASH diet, NASH research peptide, natural killer cell, nausea, NCD, NDA, Necrosis, needle safety, NEFA, nephrology, neural compensation, neurodegeneration, Neurogenesis, Neuroinflammation, neurology, neuromedin, neuropathy, neuroplasticity, neurotensin, neutralizing antibody, neutrophil, new arrival peptide, new indication, next generation peptide, niche peptide, nitrile glove, NK cell, NO production, non-coded amino acids, non-communicable disease, non-compliance, Non-human use, non-responder, noradrenaline, normal weight obese, Not for human consumption, novel compound, NPY, Nrf2, nuclear receptor, nursing, nutrient metabolism, Nutrient sensing, nutrition science, nutritional deficiency, NWO, ob/ob mouse, Obesity epidemic, obesity paradox, obesity research peptide, observational study, OCR, off-target screening, OLE, once-weekly peptide, ongoing stability, open field, Open science, open-label extension, open-source, ophthalmology, order now for research, order tracking peptide, Orexin, originator, orphan drug designation, osteopenia, osteoporosis, ovariectomy, OVX, oxidative stress, OXPHOS, oxygen consumption, PACAP, packaging integrity, pain, pair feeding study, PAL, pancreatic ablation, Pancreatic fat, pancreatic islet, pancreatic polypeptide, Pancreatitis, Parkinson's disease, participatory medicine, particle matter, partner in discovery, patent, patient advocacy group, patient centered care, patient education, patient journey, patient outcomes, patient package insert, patient satisfaction, patient stratification, patient support program, patient training, patient-led research, patient-reported outcome, payer negotiation, PayPal peptide, PBPK, PCR array, PCSK9, PD research, PDFF measurement, peace of mind research, peak sales, pediatric study, pen injector, penetration, PEPCK, peptide agitation, peptide aliquoting, peptide analysis, peptide articles, peptide availability, peptide calculator, peptide centrifugation, peptide community, peptide design, peptide distributor EU, peptide dose response, peptide formulation, peptide forum discussion, peptide half-life, peptide handling, peptide import EU, peptide labeling, peptide library, peptide library design, peptide newsletter, peptide purity test, peptide reconstitution kit, peptide research grade, Peptide stability, peptide stability assay, peptide stock solution, peptide storage container, peptide supplier Spain, peptide synthesis Europe, peptide therapeutic, peptide vendor Europe, peptides for research France, peripheral neuropathy, perivascular fat, persistence, personal protective equipment, personalized medicine, pescatarian diet, PGC-1alpha, pharmaceutical pipeline, pharmaceutical research, Pharmacogenomics, Pharmacokinetics, pharmacovigilance, pharmacy, Phase 1, Phase 2a, Phase 2b, phase 3, phosphorylation, photostability, Physical activity, physical activity guidelines, physical activity level, physiologically based PK, PI, PI3K, pivotal trial, PK/PD modeling, PKB, placebo control, Plant based diet, plaque formation, plasma insulin, platelet aggregation, plunger, PMDA, PoC study, policy, polypharmacy, POMC, population PK, position paper, positive control, post-marketing surveillance, power analysis, PP, PPAR, PPE requirement, pre-clinical trial, precision medicine, preclinical research, preference, prefilled syringe, premature mortality, premium peptide, prescriber behavior, prescribing information, preventive action, price match peptide, pricing, primary care, PRIME scheme, priority review, PRO, process validation, processing speed, product inquiry peptide, professional society, proliferation assay, proof of concept, prospective memory, prostacyclin, prostaglandin, proteasome, protectin, protein carbonyl, proteinuria, Proteomics, protocol approval, protocol assistance, pruritus, psychiatry, psychology, PTT, Public health, public health nutrition, Pyroptosis, pyruvate tolerance test, PYY, QA, QALY, QC, QC testing, QOL, quality assurance, quality control, quality of life, quality research peptides, quality system, quotation available, radiolabeled glucose, randomization, rare peptide, Rat model, raw material quarantine, raw material testing, real reviews, real-world evidence, recall, receptor binding, reconstitution device, reconstitution guide, Reddit peptide source, reduction, reference product, reference standard, referral program peptide, refinement, refund policy peptide, registration trial, Registry study, regulatory inspection, Regulatory science, regulatory submission, reimbursement, release testing, released material, remote monitoring, REMS, renal impairment, renal injury, repeat business, repeat order peptide, replacement, reporter gene assay, reproducible science, request a quote, RER, research blog, research chemicals EU compliant, research chemicals shipping, Research Compounds EU, research documentation, Research integrity, research outsourcing, research peptide protocol, Research peptide vial, research peptides EU, researcher recommendations, resistance exercise, resolvin, respiratory protection, responder analysis, resting metabolic rate, Retatrutide 100mg, Retatrutide 10mg, retatrutide 50mg, Retatrutide 99% purity, retatrutide CAS 2381089-83-2, Retatrutide clinical trial, retatrutide COA, Retatrutide cost, Retatrutide EU, retatrutide for sale, Retatrutide France achat, retatrutide HPLC, Retatrutide kaufen, Retatrutide mechanism of action, Retatrutide MOA, retatrutide molecular weight, Retatrutide MS, Retatrutide Nederland kopen, Retatrutide online Europe, Retatrutide phase 2, Retatrutide phase 3, Retatrutide price, Retatrutide purity, Retatrutide reconstitution, retatrutide sequence, Retatrutide solubility, Retatrutide storage, retest date, retinopathy, return policy peptide, risk assessment, risk management, risk management plan, risk-benefit, RMP, RMR, rockwood scale, root cause, ROS, rotarod, rubber stopper, RWE, safety biomarkers, safety data sheet, safety glasses, safety monitoring, Safety pharmacology, safety profile, safety testing, sales forecast, sample size calculation, SAR study, sarcopenia, Sarcopenic obesity, satiety, SCD1, scientific advice, scientific community, scientific consultation, scientific discovery, scientific discovery starts here, scientific progress, scientific resources, scientific statement, screening assay, SDG, SDS download, Seahorse assay, secretin, secure checkout peptide, Sedentary behavior, semantic memory, senescence, senior-friendly, sepsis, septum vial, Serotonin, serum creatinine, serum sickness, SF-36, SGLT2 inhibitor, Shared decision making, sharps disposal, short physical performance battery, shortage, side effect, signaling pathway peptide, silicone oil, silver economy, simulation, single-cell sequencing, SIRT1, sirtuins, site rotation, Sitting time, sleeve gastrectomy, sleeve protector, smart pen, smartwatch, SmPC, sNDA, SOC, social determinants of health, SOD, soft agar assay, somatostatin, spatial transcriptomics, special offer, specialist supplier, specialized pro resolving mediator, specificity profiling, spill procedure, Spinal Cord Injury, SPM, sports medicine, SPPB, SPR, stability data, stability indicating method, stability monitoring, standard of care, starting dose, statin, statistical analysis, steady state, stem cell exhaustion, sterile peptides, sterility testing, sterilization, stock up on peptides, strategic sourcing, strength training, streptozotocin, stress testing, stringent quality control, stroke, structure-activity relationship, STZ model, Subcutaneous fat, subcutaneous injection research, subscribe and save peptide, substance P, substitution, subvisible particle, sulfonylurea, summary of product characteristics, supplemental application, Supplementation, supplier audit, supply chain integrity, supply disruption, surface plasmon resonance, surgical model, sustainable development goal, swelling, Swissmedic, switch, synaptogenesis, syngeneic model, Synthetic peptide, T cell, T-score, tamper evident, target engagement, technical support peptide, TEE, telemedicine, telomerase, telomere attrition, telomere length, temperature controlled shipping, Temperature excursion, TGA, therapeutic index, therapeutic intervention, thermal stability, thermodynamic assay, Thermogenesis, thiamine, thin fat, third party tested peptides, thought leader, thrombosis, thromboxane, Time restricted feeding, timed up and go, tissue section, titration, TNF-alpha, TNF-alpha inhibitor, tocilizumab, TOFI, tolerability, total energy expenditure, toxicology research, trackable shipment, transaminase elevation, transcription factor, Transcriptomics, transgenic model, translational institute, Translational research, translational tool, transwell, Traumatic Brain Injury, treadmill running, treatment algorithm, treatment burden, treatment landscape, treatment pathway, treatment satisfaction, triglycerides, triple agonist, triple agonist peptide, TrkB, trusted by researchers, trusted peptide source, trusted site peptide, tube formation, TUG, tumor angiogenesis, tumor model, tumorigenicity, type I glass, TZD, UCP1, uncoupling protein 1, underserved population, unfolded protein response, unit dose, Universal health coverage, university lab, unrivaled quality, UPR, uptake, usability study, user interface, validation study, value peptide, vascular density, vascular reactivity, VCO2, vegan diet, vegetarian diet, VEGF expression, vendor qualification, verbal fluency, verified vendor, VES-13, veterinary research, Viability assay, vial, vigorous activity, VIP, virus testing, Visceral fat, visible particle, vision impairment, vitamin D, vitamin deficiency, VO2, volume discount, voluntary running, vomiting, vulnerable elders survey, Warburg effect, warning letter, washout period, waste management, wearable, weekend delivery peptide, weight loss, Weight loss research peptide, Weight regain, weight-related quality of life, Western blot peptide, Western diet, White paper, WHO, wholesale inquiry, wholesale peptides EU, Willingness to pay, window, working memory, wound healing, xenograft, xenohormesis, yo-yo effect, Z-score, ZDF rat

Description

Premium Retatrutide (LY3437943) for Sale | ≥99% Purity | 48-Hour Delivery Across EU & UK

Understanding GLP-3 and Retatrutide: The Next Generation of Metabolic Research Peptides

https://eupeptidelap.co.uk/ is proud to present Retatrutide, a premium research-grade triple agonist peptide often referred to in scientific discourse as a “GLP-3” class compound due to its unprecedented triple receptor targeting mechanism. As a trusted peptide vendor uk and leading EU peptide supplier, we provide researchers across Europe with Retatrutide for sale that delivers exceptional purity, consistency, and documented quality for advanced metabolic studies .

Retatrutide (LY3437943) represents a revolutionary advancement in metabolic research as the first-in-class triple agonist peptide targeting three key hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon (GCG) receptor . While not an official nomenclature, the term “GLP-3” has emerged in scientific and media discourse to describe this novel class of triple agonists that extend beyond the dual-action mechanisms of existing therapies .

The nickname “GLP-3” or “Triple-G” reflects the drug’s unique ability to harness the complementary actions of three distinct metabolic hormones, producing unprecedented effects that surpass even the most advanced dual agonists currently available . Unlike traditional GLP-1 receptor agonists that target a single pathway, or dual agonists that target two, retatrutide’s triple mechanism represents a paradigm shift in understanding how multiple hormonal signals can be coordinated to achieve superior metabolic outcomes .

The molecular formula of Retatrutide is C₂₂₁H₃₄₂N₄₆O₆₈, with a molecular weight of 4731.33 Da . Its sophisticated structure includes three non-coding amino acid residues at positions 2, 13, and 20—Aib2 provides stability from dipeptidyl peptidase-4 (DPP4) cleavage, Aib20 ensures optimal GIP activity and pharmacokinetic profile, while αMeL13 promotes balanced receptor activation . This engineered stability, combined with a C20 fatty diacid moiety that enables albumin binding, results in a long half-life of approximately 6 days, supporting once-weekly administration in clinical settings .

For researchers seeking to buy peptide online EU for investigations into metabolic disorders, obesity pharmacotherapy, type 2 diabetes, or complications of obesity such as osteoarthritis and sleep apnea, eupeptidelap.co.uk offers this premium research compound with comprehensive documentation, including Certificates of Analysis and batch-specific purity data . Whether your laboratory is based in London, Berlin, Paris, or anywhere in the European Union, our guaranteed 48 hour delivery peptide service ensures your research continues without interruption.

The Scientific Foundation of GLP-3 / Retatrutide Research

The Evolution from Single to Triple Agonism

The development of retatrutide represents the culmination of decades of research into incretin hormones and their role in metabolic regulation . First-generation therapies (GLP-1 receptor agonists like semaglutide) targeted a single hormone pathway, achieving approximately 15% average weight loss at 68 weeks . Second-generation dual agonists (GIP/GLP-1 agonists like tirzepatide) improved outcomes to approximately 21-22% weight loss .

Retatrutide, as the first triple agonist, has demonstrated the most robust results yet, with Phase 2 trials showing 24.2% weight loss at 48 weeks and Phase 3 TRIUMPH-4 trial results demonstrating 28.7% average weight loss at 68 weeks—approaching the efficacy of bariatric metabolic surgery . This progressive improvement illustrates the power of multi-receptor targeting in metabolic research.

Mechanism of Action: Triple Receptor Activation

Retatrutide exerts its effects through simultaneous activation of three key receptors, creating synergistic actions that exceed what any single pathway could achieve alone :

GLP-1 Receptor Activation: Glucagon-like peptide-1 is an incretin hormone that helps regulate appetite and signals satiety. It stimulates insulin release, lowering blood sugar, and acts on the central nervous system to reduce appetite while slowing gastric emptying .

GIP Receptor Activation: Glucose-dependent insulinotropic polypeptide is another incretin hormone released during eating. Like GLP-1, it acts as a satiety signal and increases insulin production, while also helping regulate fat metabolism and blood sugar. Activating GIP receptors is thought to enhance the effects of GLP-1 when these two actions are combined .

Glucagon Receptor Activation: The addition of glucagon agonism is what truly distinguishes retatrutide from other metabolic peptides . While glucagon alone would raise blood sugar—potentially counteracting weight loss efforts—when activated alongside GLP-1 and GIP receptors, it increases overall energy expenditure and fat burning without excessively raising blood glucose . This novel combined mechanism means retatrutide is the first metabolic peptide to target three pathways, effectively adding an “efficient combustion engine” to the “fuel limiter” effects of GLP-1 and GIP .

The “GLP-3” Nomenclature Explained

The term “GLP-3” has gained traction in both scientific and popular media to describe this new class of triple agonists . Major news outlets, including FOX NEWS, have featured discussions of “GLP-3s” as the next generation of metabolic therapies, with experts noting that the addition of glucagon agonism represents a fundamental advancement in how these drugs work .

According to media reports, if first-generation GLP-1 drugs function like installing a “fuel limiter” on the body’s energy intake, then “GLP-3” drugs like retatrutide not only limit fuel intake but also install a “high-efficiency combustion engine” (GCG activation) that actively burns excess fat . This conceptual framework helps explain the superior efficacy observed in clinical trials.

Pharmacokinetic Profile

Retatrutide has a relatively long half-life of approximately 6 days, which supports its administration as a once-weekly subcutaneous injection . This extended half-life is beneficial for maintaining steady plasma levels of the peptide, contributing to its sustained effectiveness in reducing body weight and improving metabolic parameters . Upon administration, retatrutide is absorbed and distributed efficiently throughout the body, reaching therapeutic concentrations with a predictable pharmacokinetic profile .

Key Research Applications

Obesity and Weight Loss Research

Retatrutide is extensively used in studies investigating body weight regulation, adipose tissue biology, and energy homeostasis. Clinical trials have demonstrated unprecedented weight loss results that set a new high bar for obesity pharmacotherapy research .

Phase 2 Clinical Trial Results: The landmark Phase 2 randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine demonstrated that participants receiving 12 mg weekly achieved a mean weight reduction of 24.2% of initial body weight at 48 weeks .

Phase 3 TRIUMPH-4 Trial Results: Results announced in late 2025 demonstrated even more impressive outcomes, with participants taking retatrutide 12mg losing an average of 28.7% of their body weight at 68 weeks—approximately 32.3 kg or 71.2 pounds . Among those taking the 12mg dose, 58.6% achieved ≥25% weight loss, 39.4% achieved ≥30% weight loss, and 23.7% achieved ≥35% weight loss .

These results approach the efficacy of bariatric metabolic surgery, leading some experts to describe retatrutide’s effects as “approaching the level of metabolic surgery” .

Type 2 Diabetes Research

Retatrutide has demonstrated exceptional efficacy in glycemic control research . The triple agonist mechanism provides robust improvements in glucose homeostasis through multiple pathways:

Enhanced insulin secretion through GLP-1 and GIP receptor activation
Improved insulin sensitivity
Reduced glucagon secretion when blood glucose is elevated
Beneficial effects on body composition that indirectly improve glycemic control

A systematic review of clinical trials confirmed that retatrutide leads to significant improvements in glycemic control outcomes, marking it as a promising therapeutic for type 2 diabetes mellitus .

Knee Osteoarthritis Research

The TRIUMPH-4 trial specifically evaluated retatrutide in 445 adults with obesity or overweight and knee osteoarthritis . Results showed remarkable improvements:

Pain scores improved substantially, with retatrutide reducing Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores by up to 4.5 points (approximately 75.8%), compared with a 2.4-point (40.3%) reduction with placebo .
In a post-hoc analysis, approximately 1 in 8 (12.5%) retatrutide-treated participants reported being completely free of knee pain at week 68, compared with just over 4% of placebo recipients .
Measures of physical function improved, with reductions in the WOMAC function subscale exceeding 70% for both retatrutide doses .

Researchers note that these improvements likely stem from both weight reduction (reducing mechanical stress on joints) and the drug’s anti-inflammatory effects, lowering systemic inflammation markers .

Obstructive Sleep Apnea Research

The TRIUMPH clinical development program includes dedicated evaluation of retatrutide for obstructive sleep apnea (OSA), a common complication of obesity . The TRIUMPH-1 and TRIUMPH-2 trials include OSA-specific endpoints, measuring change in Apnea-Hypopnea Index (AHI) as a primary outcome .

Given that substantial weight reduction is often required to meaningfully improve OSA, retatrutide’s unprecedented efficacy positions it as a particularly promising candidate for OSA research .

Cardiovascular Risk Factor Research

Retatrutide has demonstrated significant improvements in multiple cardiovascular risk markers :

Blood Pressure Reduction: At the highest dose, systolic blood pressure decreased by 14.0 mmHg .
Lipid Improvements: Retatrutide lowered non-HDL cholesterol and triglycerides .
Inflammation Reduction: The drug reduced high-sensitivity C-reactive protein (hsCRP), a sensitive marker of cardiovascular risk .

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Research

Retatrutide shows promise in addressing metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease . The combination of weight reduction, improved insulin sensitivity, and direct effects on hepatic fat metabolism through glucagon receptor agonism makes it particularly relevant for liver disease research .

Quality Assurance: Setting the Standard for Research Compounds

Manufacturing Excellence

eupeptidelap.co.uk sources Retatrutide from certified GMP facilities with rigorous quality control protocols:

HPLC Purity Analysis: ≥99% purity verified by high-performance liquid chromatography
Mass Spectrometry Verification: Molecular weight confirmation via LC-HRMS
Batch-Specific Certificates of Analysis: Complete documentation for each production run
Third-Party Lab Testing: Independent verification of purity and potency
Regulatory Compliance: Research Use Only (RUO) labeling with proper documentation

Chemical and Product Specifications

Specification	Detail
Product Name	Retatrutide (LY3437943) – R&D Only
CAS Number	2381089-83-2
Molecular Formula	C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight	4731.33 Da
Amino Acid Length	39 amino acids
Purity	≥99% (HPLC verified)
Appearance	White to off-white lyophilized powder
Form	Lyophilized powder
Solubility	Soluble in water, PBS, and appropriate buffers
Mechanism	Triple GLP-1/GIP/Glucagon receptor agonist
Half-Life	Approximately 6 days
Key Research Areas	Obesity, type 2 diabetes, osteoarthritis, sleep apnea, MASLD, cardiovascular risk
Storage (Powder)	-20°C; protect from light and moisture
Storage (Reconstituted)	2-8°C for short-term; aliquot and freeze at -20°C for longer storage
Shipping	Ambient temperature with protective packaging
Intended Use	Research and laboratory use only
Documentation	Certificate of Analysis provided with each batch

Stability and Handling Guidelines

Lyophilized Powder Storage: Retatrutide powder should be stored at -20°C in a dry, dark environment, protected from light and moisture. Use manual-defrost freezers and store vials in the back (not doors) to avoid temperature fluctuations.

Reconstitution Protocol:

Allow vial and solvent to reach ambient temperature before opening to prevent condensation
Reconstitute using sterile water, PBS, or appropriate buffer according to research protocol
Gently swirl until powder is completely dissolved—do not shake vigorously
Use fresh sterile needles for each vial access
Clean rubber stoppers with alcohol swabs before each puncture

Reconstituted Solution Storage: Once reconstituted, retatrutide solutions should be stored at 2-8°C for short-term use. For longer-term storage, aliquot into single-use portions and freeze at -20°C. Avoid repeated freeze-thaw cycles as this can degrade the peptide.

Protection from Light and Moisture:

Store in amber vials or protect from light
Keep vials tightly sealed when not in use
Allow frozen vials to reach room temperature before opening to prevent condensation.

Key Benefits

Premium Quality Manufacturing: GMP-certified production, ≥99% HPLC-verified purity
First-in-Class Triple Agonist: Simultaneous GLP-1, GIP, and glucagon receptor activation for synergistic research applications
Unprecedented Weight Loss Research: Enables investigation of 24-29% body weight reduction in obesity models
Superior Efficacy: Phase 3 results demonstrate 28.7% average weight loss at 68 weeks—approaching metabolic surgery outcomes
Knee Osteoarthritis Research: Reduces WOMAC pain scores by up to 75.8% with 1 in 8 participants achieving complete pain resolution
Sleep Apnea Research: Dedicated OSA endpoints in TRIUMPH program for comprehensive investigation
Cardiovascular Risk Research: Reduces systolic blood pressure, non-HDL cholesterol, triglycerides, and hsCRP
MASLD/NAFLD Research: Potential applications in metabolic dysfunction-associated steatotic liver disease
Type 2 Diabetes Research: Significant improvements in glycemic control outcomes
Energy Expenditure Studies: Glucagon agonism increases metabolic rate through enhanced fat burning
Appetite Regulation Research: Triple mechanism targeting satiety and reward pathways
Inflammation Research: Reduces systemic inflammation markers independent of weight loss
Extended Half-Life: Engineered stability with C20 diacid for albumin binding and prolonged duration
DPP-4 Resistant: Aib2 modification provides enzymatic stability
Comprehensive Documentation: Certificates of Analysis with batch-specific purity data
48-Hour EU & UK Delivery: Rapid shipping to research facilities across Europe
Batch Consistency: Rigorous quality control ensures lot-to-lot reproducibility
EU Sourced: Available from within the European Union

Frequently Asked Questions

Q: What is GLP-3 and how does it relate to Retatrutide?

A: “GLP-3” is an informal term that has emerged in scientific and popular media to describe the new class of triple agonist peptides like retatrutide that target GLP-1, GIP, and glucagon receptors simultaneously . While not an official pharmacological classification, the term captures the evolutionary progression from single-action GLP-1 drugs to dual-action GIP/GLP-1 agonists to this new triple-action mechanism . Retatrutide is the first-in-class triple agonist in this category.

Q: Is Retatrutide approved for human use?

A: No. Retatrutide from eupeptidelap.co.uk is strictly for research and laboratory use only. It is not for human or animal consumption, and must not be used for therapeutic, diagnostic, or clinical applications. While retatrutide is currently in Phase 3 clinical trials (expected to complete in 2026) and may receive regulatory approval in 2027, research-grade material is intended for investigational purposes only . Researchers must handle this compound in accordance with institutional safety guidelines and local regulations.

Q: What is the legal status of Retatrutide for research in the UK?

A: The sale of unlicensed peptides like retatrutide under “research use only” labeling is permissible under strict conditions for legitimate research purposes. Proper documentation including Certificates of Analysis, Safety Data Sheets, and explicit RUO labeling is mandatory. Researchers should note that unlicensed, illegal versions of retatrutide have reportedly already been sold online, making it essential to source from reputable suppliers with proper documentation .

Q: What purity level can I expect when I buy Retatrutide from eupeptidelap.co.uk?

A: All Retatrutide from eupeptidelap.co.uk is tested to ≥99% purity by HPLC. Each batch is individually analyzed, and Certificates of Analysis are provided with every order, ensuring you receive material suitable for rigorous research applications.

Q: How effective is Retatrutide for weight loss in research models?

A: In clinical trials, retatrutide has demonstrated unprecedented weight loss results. Phase 2 studies at 48 weeks showed 24.2% average weight loss at 12 mg dose . Phase 3 results at 68 weeks demonstrated 28.7% average weight loss (approximately 32.3 kg / 71.2 pounds) . This represents the highest weight loss recorded for any anti-obesity medication to date, approaching the efficacy of bariatric metabolic surgery .

Q: How should I store Retatrutide for long-term stability?

A: Store lyophilized retatrutide powder at -20°C, protected from light and moisture. After reconstitution, store at 2-8°C for short-term use. For longer-term storage, aliquot into single-use portions and freeze at -20°C. Avoid repeated freeze-thaw cycles as this can degrade the peptide.

Q: What is the mechanism of action of Retatrutide?

A: Retatrutide is a first-in-class triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously . GLP-1 and GIP enhance insulin secretion, suppress appetite, and slow gastric emptying, while glucagon increases energy expenditure and promotes fat breakdown. The glucose-lowering effects of GLP-1 and GIP offset glucagon’s potential blood sugar-raising effects, creating a synergistic system .

Q: What research areas commonly use Retatrutide?

A: Retatrutide is widely used in obesity and weight loss research, type 2 diabetes research, knee osteoarthritis research, obstructive sleep apnea research, cardiovascular risk research, MASLD/NAFLD research, and inflammation research .

Q: Do you ship Retatrutide to EU countries?

A: Yes. As a dedicated EU peptide supplier, we ship Retatrutide to all European Union member states with our guaranteed 48 hour delivery peptide service. Our EU fulfilment centre ensures rapid delivery without customs delays. All shipments use protective packaging to maintain compound integrity during transit.

Q: What documentation do you provide with Retatrutide orders?

A: Every order includes a Certificate of Analysis with batch-specific purity data. Additional documentation, including HPLC chromatograms and mass spectrometry data, is available upon request for researchers requiring comprehensive analytical verification. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Q: How does Retatrutide compare to other metabolic peptides?

A: Retatrutide (triple GLP-1/GIP/glucagon agonist) represents an advancement beyond semaglutide (GLP-1 only, ~15% weight loss) and tirzepatide (dual GIP/GLP-1, ~21-22% weight loss) . Phase 3 results showing 28.7% weight loss at 68 weeks demonstrate the enhanced efficacy of triple agonism . The addition of glucagon agonism drives enhanced effects on energy expenditure and fat metabolism not addressed by dual agonists. ...........................................

Q: What are the ongoing clinical trials for Retatrutide?

A: The Phase 3 TRIUMPH program includes multiple trials: TRIUMPH-1 (weight management with OA/OSA subsets), TRIUMPH-2 (weight management with T2D and OSA subsets), TRIUMPH-3 (obesity with CVD), and TRIUMPH-4 (knee osteoarthritis) . These studies have enrolled over 5,800 participants, with results expected throughout 2026 .

Q: Does Retatrutide have applications in osteoarthritis research?

A: Yes, dramatically. The TRIUMPH-4 trial demonstrated that retatrutide reduced WOMAC pain scores by up to 75.8%, with approximately 12.5% of participants reporting complete pain resolution . These improvements likely stem from both weight reduction (reducing mechanical stress) and direct anti-inflammatory effects .

Q: Do you offer bulk quantities of Retatrutide for institutional research?

A: Yes. We accommodate bulk orders for research institutions. Contact our team at sales@eupeptidelap.co.uk for volume pricing, custom requirements, and supply agreements for ongoing research programs.

Advance Your Research with GLP-3 | Retatrutide

eupeptidelap.co.uk is your trusted source for Retatrutide, the premium choice for researchers investigating metabolic disorders, obesity pharmacotherapy, diabetes, and obesity-related complications. As the first-in-class triple GLP-1/GIP/glucagon receptor agonist—often referred to as a “GLP-3” or “Triple-G”—retatrutide represents a revolutionary tool for exploring the synergistic actions of all three metabolic pathways and their unprecedented therapeutic potential .

Whether you are exploring weight loss mechanisms, designing diabetes studies, investigating osteoarthritis, or researching cardiometabolic outcomes, our rigorously tested compound provides the quality and consistency your work demands.

Order today and experience the eupeptidelap.co.uk difference – premium quality, rapid 48-hour delivery across the EU and UK, and expert support for the European research community.

Sign up for Newsletter